2019 Speakers

Václav first investigated machine learning & medical imaging to help doctors diagnose cancer a decade before it became practical. He holds a M.Phil from the University of Cambridge, funded by Microsoft Research, and a Doctorate (D.Phil) from the University of Oxford supervised by Prof. Sir Mike Brady and Dr. Timor Kadir, based at Siemens Molecular…

Lyn Baranowski is the COO of Altavant Sciences. She has significant experience in the respiratory therapeutic area leading commercial, transactional, financial and strategic functions. This experience spans roles in multiple biotech companies (Pearl Therapeutics and Melinta Therapeutics), big pharma (Novartis) and venture capital (Vatera Healthcare), giving Ms. Baranowski a unique perspective on how to build…

Dr. Lord serves as Head of Research and Development and is responsible for directing and overseeing all aspects of the development lifecycle for programs within the company’s portfolio. He has more than 26 years of inhalation product development experience including leadership roles at pharmaceutical companies like Rhône-Poulenc Rorer and Nektar Therapeutics. He has experience across…

Isai Peimer is a Biotech Analyst at Surveyor Capital (Citadel) where he focuses on public/private investments across the biotechnology sector. From 2010 to 2016, Isai served as a Managing Director at Medimmune Ventures, Astrazeneca’s investment fund. Isai has served as board member of Adheron Therapeutics (Acquired by Roche), Ambit Biosciences (acquired by Daiichi Sankyo), Armaron…

Rob Tarran is a Professor in UNC’s Department of Cell Biology and Physiology and is also a member of UNC’s Lineberger Cancer Center and Marsico Lung Institute. Rob has over 20 years of experience in studying airway disease and is particularly interested in the role of ion channels in disease pathogenesis. Rob has focused on…

David S. Joseph, his career spans forty years of highly successful hospital management and entrepreneurship as a founder of five companies involved in surgical lasers, orthopedic biomaterials, medical devices and pharmaceuticals. Former co-founder, president and chairman Orthovita an orthopedics bio materials company and initiated a public offer and subsequently acquired by Stryker Corporation. He co-founded…

Doug is the CEO of Lungpacer Medical Inc., which is developing a novel Breakthrough Device designed to improved outcomes for critically ill mechanically ventilated patients. He was formerly the Chief Operating Officer of Kensey Nash (KNSY); acquired for $360M by Royal DSM, and prior to that at GE. He is a serial innovator and product…

After working for the Glaxo family of companies for over 20 years, followed by a short period of consulting, I co-founded Respivert Ltd in 2007 to discover novel inhaled anti-inflammatory agents to treat COPD. The company was VC funded and was acquired in 2010. I then I continued to work on the Respivert portfolio of…

Dr. Kan has been working in the pharmaceutical industry for more than 20 years, focused on pharmaceutical formulation technology and product development, published over 50 papers and more than 10 patents related to drug delivery, some of which have been used in clinical products. He is now the President of Pharmosa and has served in…

Dr. Rose is an experienced health care executive with broad experience in science, medicine and medical product development. He is a graduate of Yale College and the Harvard Medical School, where he was an Associate Professor of Medicine and Chief of the Division of Pulmonary and Critical Care Medicine at Beth Israel Deaconess Hospital. He…